Phenylalanine (4)-hydroxylase (PAH, E.C. 1.14.16.1) is located mainly in liver and converts amino acid phenylalanine (Phe) to tyrosine (Tyr). In 'classical' phenylketonuria (PKU), PAH activity is reduced, whereas in 'atypical' PKU biosynthesis of the cofactor 5,6,7,8-tetrahydrobiopterin (BH4) is disturbed. Aside from these inherited conditions, elevated plasma Phe concentrations and increased Phe to Tyr ratios (Phe/Tyr) were observed in patients with cancer, burns, sepsis and HIV-1 infection. Results indicate that immune activation and inflammation are associated with moderate impairment of PAH activity. This review discusses findings of increased Phe/Tyr in patients suffering from chronic inflammatory diseases, their clinical relevance and consequences.
Introduction
Phenylalanine (Phe) is an essential amino acid for humans and has to be supplied with nutrition. Natural proteins contain approximately 4.5 -5 % Phe (1) . The daily requirement of Phe and tyrosine (Tyr) in adults is set at 14 mg/kg.d (2) . Aside from its role as a constituent of proteins, Phe is also substrate of the enzyme phenylalanine 4-hydroxylase (PAH, EC 1.14.16.1) which is located mainly in the liver and converts Phe to Tyr (3) (Fig. 1) . The PAH gene is located on chromosome 12q24.1 and contains 13 exons (3) . Approximately 67 -90 % of Phe enters the pathway of Tyr biosynthesis (1, 4) . Additionally, the PAH gene is expressed in kidney and other extrahepatic organs (5) .
PAH activity is the rate limiting step in Phe catabolism. 5, 6, 7, ) is the cofactor of this enzyme and of Tyr-and tryptophan-hydroxylase (6) , nitric oxide synthases (7) and of alkylglycerol monooxygenase, as it has been identified just recently (8) (Fig. 1) . BH 4 is synthesized from guanosine triphosphate (GTP) by at least four enzymatic steps. The first of it, catalyzed by GTP cyclohydrolase I (GTP-CH, EC 3.5.4.16), is regulated by Phe (positively) and BH 4 concentrations (negatively), (9) . 
(-CH3) Figure 1 . Biochemistry of L-phenylalanine: L-Phenylalanine is an essential proteinogenic amino acid and also a precursor of biogenic amines. Phenylalanine 4-hydroxylase (PAH, EC 1.14.16.1) is the rate-limiting enzyme, which introduces a hydroxy-group to phenylalanine to form L-tyrosine. L-tyrosine is further converted to L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine 3-hydroxylase (T3H, EC 1.14.16.2). Both enzymes, PAH and T3H, require 5,6,7,8-tetrahydrobiopterin (BH 4 ) as a cofactor. Tyrosine is then metabolized to the catecholamines dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline).
Tyr, the product of PAH, can be further converted in the liver via tyrosine 3-hydroxylase (EC 1.14.16.2) which is also BH 4 -dependent and produces L-3,4-dihydroxyphenylalanine (L-DOPA), the precursor of several important products like the catecholamines dopamine, epinephrine (adrenaline), norepinephrine (noradrenaline), and melanin and thyroxine. The concentrations of plasma or serum Phe and Tyr are agedependent, with higher concentrations in very young subjects (10) . In adults plasma Phe concentrations are usually lower than 75 µmol/L (reference values for men 46-74 µmol/L and women 42-62 µmol/L (11)), and plasma Tyr concentrations are lower than 78 µmol/L (reference values for men 37-77 µmol/L and women 26-78 µmol/L (11)).
Elevations of phenylalanine concentrations
Phe metabolism can be disturbed primarily due to genetically determined PAH deficiency or secondarily by reduction of PAH activity by metabolites.
Primary causes of elevated Phe concentrations include phenylketonuria (PKU). In 'classical' PKU, activity of PAH is reduced (3), whereas in 'atypical' PKU biosynthesis of the cofactor BH 4 is disturbed (8) . Thus in patients with BH 4 deficiency, the aromatic amino acid hydroxylases besides PAH are disturbed as well. This leads to reduced production of neurotransmitters from Tyr and tryptophan and to clinical symptoms despite a Phe-restricted diet.
Secondary causes of diminished PAH activity and subsequently elevated plasma Phe concentrations include liver diseases, where the ratio of branched chain amino acids to aromatic amino acids (also known as Fischer's ratio) is decreased (12) . Preanalytical problems like postprandial blood sampling or circadian rhythm also can influence plasma Phe concentrations. Additionally, it was shown that in subgroups of patients with burns (13, 14) , sepsis (15, 16) , HIV-1 infection (17,18) and ovarian cancer (19) may present with elevated plasma Phe concentrations. This is especially true, when Phe levels are expressed as percent of total amino acids. The underlying background of this moderate hyperphenylalaninemia is still obscure, but most likely it develops due to reduced PAH activity in a situation where the catabolic state of the patient contributes to an accumulation of Phe. The associations found between the increased Phe concentrations and immune activation markers like neopterin imply an involvement of inflammation and immune activation in this impaired PAH activity (20) . Since BH 4 is chemically very labile and can easily be oxidized, diminution of PAH activity can result from irreversible oxidation of the necessary cofactor, when high output of reactive oxygen species (ROS) may occur during inflammatory conditions. Alternatively or in addition, ROS were shown to influence tertiary structure of proteins (21) and may thus also affect enzymes like PAH (22) and impair binding of the substrate and/or the cofactor.
Phenylalanine to tyrosine ratio (Phe/Tyr)
PAH converts the essential amino acid Phe to Tyr and thus, the ratio of concentrations of the substrate Phe to the product Tyr (Phe/Tyr) is a useful measure to estimate PAH activity (3, 23) . However, Phe/Tyr cannot provide precise information about PAH, because Tyr is not a biochemical end product ( Fig.1 ) and its concentrations are also influenced by the activity of L-DOPA-forming enzyme tyrosine 3-hydroxylase and others. In patients with untreated inborn disorders of Phe metabolism like PKU, Phe/Tyr is constantly elevated, reflecting the underlying pathomechanisms of these disorders. In DOPA-responsive dystonia (DRD), a Phe loading (100 mg/kg bw) with determination of Phe/Tyr is of diagnostic relevance. Patients with DRD have ratios above 5.4 (= 2h-value, (24)). In healthy persons the cut off for Phe/Tyr is suggested to be 1.15 (25) . Recently, in relevant proportions of patients with HIV-1 infection (18), burns (13, 14) , sepsis (15, 16) and women with ovarian cancer (19) , elevated Phe/Tyr were shown. Additionally, neuroinflammatory disorders were more often observed in children with elevated Phe/Tyr (26) .
Neopterin
Neopterin (6-D erythro trihydroxypropylpterin) is formed via 7,8-dihydroneopterin triphosphate, which is the first rather stable product of GTP-CH (9) (Fig.  2) . After elimination of the triphosphate and dehydration, D-erythro-neopterin and 7,8-dihydroneopterin are formed. Once synthesized, neopterin is stable and concentrations in various body fluids, including cerebrospinal fluid and urine are representative for its production rate (27) -only exposure to UV-light may initiate its decomposition (28) .
Like Phe concentrations, neopterin concentrations can be elevated primarily or secondarily. Primary causes of neopterin elevations are inborn disorders of biopterin biosynthesis, when conversion of 7,8-dihydroneopterin triphosphate is disturbed (9) . In atypical PKU with intact GTP-CH activity but a diminished enzyme machinery for the conversion of 7,8-dihydroneopterin triphosphate to form BH 4 , neopterin concentrations are elevated characteristically together with low concentrations of biopterin derivatives. However, this subcategory of atypical PKU is very rare and beyond the scope of this review. Secondarily elevated neopterin concentrations develop in humans and primates upon activation of monocyte-derived macrophages and dendritic cells within the cellular (= Th1-type) immune response (29, 30) . Thereby, Th1-type lymphocytes release among other cytokines interferon-γ (IFN-γ), which stimulates GTP-CH, and because human macrophages and dendritic cells possess only low constitutive activity of 6-pyruvoyltetrahydropterin synthase (PTPS), this leads to accumulation of neopterin at the expense of BH 4 . In parallel, IFN-γ induces high output of reactive oxygen species (ROS) (31) , and the generation of oxidizing metabolites such as hydrogen peroxide (H 2 O 2 ) or superoxide anion (O 2 -). Thus, whenever increased neopterin concentrations are observed in patients with inflammatory conditions, also ROS production and the development of oxidative stress can be assumed (Fig.  2) . Neopterin was also found to have pro-oxidative properties and may contribute to further accelerate the pro-inflammatory response (32, 33) . As a matter of fact, in patients with coronary artery disease an inverse association has been already described between concentrations of neopterin and several antioxidants including vitamin C and E and lutein and zeaxanthine (34) . One should expect that in any condition in which antioxidants are depleted due to overwhelming production of ROS, also BH 4 availability will become impaired and thus Phe concentrations and Phe/Tyr may increase (Fig. 3) (24) . Interestingly enough, from children suffering from atypical PKU and under chronic supplementation with BH 4 , it is known that during infectious episodes transient increases of blood Phe concentrations (blips) can occur (35) . Likewise, BH 4 deficiency has also been described in human rabies (36) . The exact background of such findings is unclear until now, but indeed they may relate to an increased requirement of BH 4 in situations of an inflammatory response, which goes along with oxidative stress and increased degradation of antioxidants such as BH 4 .
Correlation of Phe/Tyr and neopterin
Recent studies demonstrate a correlation between neopterin concentrations and Phe/Tyr as well as absolute Phe concentrations in plasma of patients after 4 ) and in parallel high output of reactive oxygen species (ROS), which wipe out antioxidant pools including BH 4 and oxidative stress develops. BH 4 -dependent enzymes begin to suffer as activity of the liver enzyme phenylalanine 4-hydroxylase becomes impaired. As a consequence, phenylalanine concentrations begin to rise. trauma and with sepsis (Ploder et al 2008) , in patients with ovarian cancer (25) and in patients with HIV-1 infection (Fig. 4) (17) . Moreover, in patients with HIV-1 infection a spontaneous decline of Phe/Tyr was observed after successful antiretroviral therapy (18) . Given that Phe/Tyr represents an estimate of PAH activity and that increased neopterin concentrations in those patients indicate an inflammatory response (29) , one is forced to conclude that moderate hyperphenylalaninemia in these disorders derives from immune response-associated biochemical changes. The recent finding that Phe/Tyr also increases in patients with malignant melanoma during treatment with interferon-α (IFN-α , further substantiates this conclusion (37) .
Inflammation-induced impairment of PAH may express many-fold influences on the neuropsychiatric performance of patients suffering from clinical conditions associated with inflammation and/or immune activation, e.g., impaired dopamine and noradrenaline metabolism may also impact the hypothalamic-pituitary-adrenal (HPA) axis. In fact, a study in elderly individuals already revealed that higher Phe/Tyr is associated with general behavioral and neurovegetative symptoms such as sleep alterations, sickness digestive symptoms and motor symptoms (38) .
Extended studies of the relationship between Phe/Tyr and neuropsychiatric symptoms are still not available in chronic inflammatory conditions. However, especially in combination with measurements of tryptophan degradation, elevated Phe/Tyr could represent a new option to differentiate patients whether dopaminergic treatment strategies are more likely to be effective or serotonergic treatment in case of patients with an elevated kynurenine to tryptophan ratio as index of tryptophan degradation (39) .
Future prospects
The association found between immune activation, inflammation and alterations of specific biochemical pathways opens a new avenue for considerations how an inflammatory background may contribute to neuropsychiatric abnormalities in patients. It will be important to extend such clinical studies to further sub- stantiate these findings. However, the determination of Phe/Tyr in patients will be helpful to detect moderate changes of a specific biochemical pathway, which allows insight into BH 4 -dependent enzyme activities. This could be especially important in patients with genetic predispositions such as, e.g., heterozygosity of the phenylalanine hydroxylase gene.
The possible role of oxidative stress in the destruction of BH 4 but also the possible modification of the tertiary structures of enzymes may provide new therapeutic options, e.g. the substitution of BH 4 in patients with severe immunologic/inflammatory disorders and elevated Phe. The parallel measurement of Phe/Tyr and immune activation markers like neopterin could lead to a new therapeutic option. Alternatively, also supplementation with antioxidants such as vitamins C and E could be of benefit (40) . Vitamin C is already uses to stabilize BH 4 for therapeutic applications.
